Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
The latest in news from I-MAK experts.
For press inquiries, please contact simon@i-mak.org.
The Battle for Erlotinib – High Court Decision Raises a Number of Procedural and Practice Issues
Tussle Over Participation In India Compulsory Licence Hearing – IP Watch By Tatum Anderson
Patent Granted for Raltegravir in India
USPTO finds Gilead’s Tenofovir patents invalid following re-examination request by PUBPAT
Unravelling the Valganciclovir patent question in India
Unravelling the Valganciclovir patent question in India
I-MAK Joins Groups in Filing a Public Interest Amici Brief Supporting New U.S Patent Rules
Raltegravir application still pending in India
How do we increase transparency on granted drug patents?
New Push Emerges For An Indian Patent Database – By Kaitlin Mara of IP Watch